Clinical Trial Update: Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant pembrolizumab for muscle-invasive urothelial bladder carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Urothelial Bladder Carcinoma | Phase 2 | Status: COMPLETED